# CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

> **NCT03236987** · PHASE3 · RECRUITING · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 424 (estimated)

## Conditions studied

- Lung Infection
- MAC Lung Disease

## Interventions

- **DRUG:** Clarithromycin 1000 MG
- **DRUG:** Azithromycin 250 mg
- **DRUG:** Rifampicin
- **DRUG:** Ethambutol

## Key facts

- **NCT ID:** NCT03236987
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-05
- **Primary completion:** 2028-02-05
- **Final completion:** 2029-02-05
- **Target enrollment:** 424 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236987, "CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03236987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*